OPKO Health (NASDAQ:OPK - Get Free Report) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.03), Briefing.com reports. OPKO Health had a negative return on equity of 12.69% and a negative net margin of 21.76%. The business had revenue of $173.70 million during the quarter, compared to the consensus estimate of $182.99 million. During the same quarter in the prior year, the company posted ($0.02) earnings per share. The company's revenue for the quarter was down 26.9% on a year-over-year basis.
OPKO Health Stock Performance
Shares of OPKO Health stock traded down $0.05 during midday trading on Wednesday, hitting $1.25. The company had a trading volume of 5,436,284 shares, compared to its average volume of 12,339,308. OPKO Health has a 1-year low of $0.85 and a 1-year high of $2.24. The business's 50 day simple moving average is $1.14 and its two-hundred day simple moving average is $1.22. The stock has a market cap of $871.24 million, a PE ratio of -5.00 and a beta of 1.81. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.55 and a quick ratio of 1.22.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on OPK shares. StockNews.com lowered OPKO Health from a "hold" rating to a "sell" rating in a report on Friday, March 1st. HC Wainwright reaffirmed a "buy" rating and set a $3.00 price objective on shares of OPKO Health in a report on Wednesday. Barrington Research reiterated an "outperform" rating and issued a $1.50 target price on shares of OPKO Health in a report on Monday, April 1st. Finally, Piper Sandler reissued an "overweight" rating and set a $5.00 target price on shares of OPKO Health in a research report on Monday, April 1st.
View Our Latest Stock Analysis on OPK
Insider Activity at OPKO Health
In related news, CEO Phillip Md Et Al Frost acquired 500,000 shares of the company's stock in a transaction dated Wednesday, February 28th. The shares were bought at an average price of $0.99 per share, for a total transaction of $495,000.00. Following the acquisition, the chief executive officer now owns 208,868,225 shares in the company, valued at approximately $206,779,542.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders purchased a total of 3,100,000 shares of company stock worth $2,923,000 in the last ninety days. 47.26% of the stock is currently owned by insiders.
About OPKO Health
(
Get Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
See Also
Before you consider OPKO Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OPKO Health wasn't on the list.
While OPKO Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
